Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLI-489 · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | BLI-489 |
| 2 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| BLI-489 | DRUG | - |
| placebo | DRUG | - |
| BLI-489/Piperacillin | DRUG | - |
| Piperacillin | DRUG | - |
Inclusion Criteria: * Men or women of non-childbearing potential (WONCBP) aged 18 to 50 years inclusive at screening; * Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight ≥50 kg.; * Healthy as determined by the investigator on the basis of screening evaluations; * Calculated creat...
BLI-489 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in Phase 1 clinical trials involving healthy adult volunteers, including a study of BLI-489 combined with piperacillin. No patient indication has been disclosed for the program.
BLI-489 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 clinical program for the compound, including trials conducted in the United States and Japan.
BLI-489 is in Phase 1 development. All four of its recorded clinical trials are Phase 1 studies, and all four are completed, with no active trials ongoing. It is an investigational agent and has not been approved by the FDA.
BLI-489 has been evaluated in four completed Phase 1 trials: NCT00909688, a multiple-dose tolerability study in healthy subjects; NCT00894439, a study of BLI-489 and piperacillin in healthy subjects; NCT00854009, a single-dose study in healthy Japanese male subjects; and NCT00820404, a single-dose study in healthy subjects.
Across the four completed Phase 1 trials, 134 participants have been enrolled. The studies were randomized, double-blind, and placebo-controlled, and all enrolled healthy volunteers rather than patients with a disclosed disease indication.